Targeting Immunosenescence: Combining Senolytics with Immunotherapy Improves Outcomes in Head and Neck Squamous Cell Carcinoma

Highlight

Recent phase 2 trial data demonstrate that combining senolytic drugs with anti-PD-1 immunotherapy in head and neck squamous cell carcinoma (HNSCC) patients improves major pathological response rates to 33.3% with low high-grade adverse events (4.2%). Single-cell RNA sequencing reveals that immunosenescence markers in T and B cell subsets correlate with poor outcomes, identifying immune aging as a key resistance mechanism. Preclinical models showed senolytics mitigate immunosenescence, enhancing immunotherapy efficacy across solid tumors.

Study Background and Disease Burden

Head and neck squamous cell carcinoma is a significant global health burden with a high mortality rate and limited effective treatment options, especially in locally advanced disease. Despite advances, immunotherapy with immune checkpoint inhibitors such as anti-PD-1 antibodies has yielded moderate response rates, and many patients experience progression or relapse. One contributing factor may be immunosenescence—age-related functional decline of the immune system—which is known to impair immune surveillance and response but is incompletely understood in the context of solid tumors like HNSCC. Clarifying how immunosenescence shapes therapeutic outcomes is crucial for improving immunotherapy strategies and patient prognosis.

Study Design

The investigators conducted a phase 2 clinical trial (COIS-01, ClinicalTrials.gov NCT05724329) enrolling 51 patients diagnosed with HNSCC. Participants received neoadjuvant chemoimmunotherapy followed by surgical resection. The intervention group additionally received senolytic agents combined with anti-PD-1 therapy. Comprehensive immune profiling was performed using single-cell RNA sequencing along with T-cell receptor (TCR) and B-cell receptor (BCR) sequencing on paired tumor and peripheral blood samples to delineate immune cell perturbations. Furthermore, aged and Ercc1-deficient mice, modeling natural and premature aging respectively, were used for mechanistic studies assessing the effects of senolytics on immunotherapy response across multiple solid tumor types.

Key Findings

Immune profiling revealed that poor clinical response to chemoimmunotherapy correlated with significantly reduced levels of CCR7+ CD4+ naive T cells and CD27+ memory B cells, both critical for robust adaptive immune responses. Higher expression of immunosenescence-associated gene signatures in T and B cell subsets was also linked to unfavorable outcomes, suggesting an age-associated immune dysfunction impairs therapy efficacy.

Preclinical data from aged and Ercc1-deficient mouse models demonstrated that senolytic treatment effectively reduced markers of immune cell senescence and enhanced the antitumor efficacy of immune checkpoint blockade. This supports a causal role for immunosenescence in therapeutic resistance and positions senolytics as immune rejuvenation agents.

In the clinical trial, the combination of senolytics with anti-PD-1 therapy yielded a major pathological response (MPR) rate of 33.3% (95% confidence interval 16.6–54.7%), surpassing historical response rates seen with immunotherapy alone. Importantly, the incidence of grade 3–4 adverse events was low at 4.2%, indicating a favorable safety profile for the combination regimen.

These results collectively highlight immunosenescence as a modifiable barrier to immunotherapy and establish a proof of concept for senolytic augmentation in human cancer treatment.

Expert Commentary

The study by Liu et al. represents a significant step in understanding how immune aging negatively impacts cancer immunotherapy and rigorously demonstrates that targeting senescent immune cells can restore responsiveness. By integrating cutting-edge single-cell analyses with translational preclinical and clinical investigations, this trial provides compelling evidence for senolytics as a new adjunctive class of immunotherapeutics in HNSCC.

While encouraging, limitations include the modest sample size and relatively short follow-up. Additional larger randomized studies with long-term outcome data are warranted to confirm durability of response and survival benefit. Furthermore, mechanistic exploration of differential senolytic effects on immune subsets could refine patient selection and therapeutic dosing. The findings are consistent with recent literature linking immunosenescence to tumor immune evasion and underscore the value of immune biomarkers like CCR7+ CD4+ naive T and CD27+ memory B cells for patient stratification.

Conclusion

The integration of senolytics with anti-PD-1 immunotherapy in HNSCC shows promising efficacy and safety, addressing the unmet need of overcoming immunotherapy resistance mediated by immunosenescence. This innovative approach opens avenues for broader application of immune rejuvenation strategies in oncology, particularly for older patient populations with age-associated immune decline. Future clinical trials should focus on optimizing senolytic regimens, validating predictive immune biomarkers, and assessing long-term clinical benefit to refine this promising therapeutic paradigm.

References

1. Liu N, Wu J, Deng E, et al. Immunotherapy and senolytics in head and neck squamous cell carcinoma: phase 2 trial results. Nat Med. 2025. https://doi.org/10.1038/s41591-025-03873-7
2. Pawelec G, Goldeck D, Derhovanessian E. Inflammation, ageing and chronic disease. Curr Opin Immunol. 2014;29:23-28.
3. Teijaro JR, et al. Immunosenescence and the role of senolytics in cancer therapy. Trends Immunol. 2023;44(7):574-586.
4. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350-1355.
5. Childs BG, Baker DJ, Kirkland JL, Campisi J, van Deursen JM. Senescence and apoptosis: dueling or complementary cell fates? EMBO Rep. 2014;15(11):1139-1153.